BAILLIE GIFFORD OVERSEAS LTD — 13F Portfolio

BAILLIE GIFFORD OVERSEAS LTD is a UK-based investment management company and a core operating entity within the Baillie Gifford partnership headquartered in Edinburgh, Scotland. The firm serves predominantly non-UK clients, including U.S. institutions and mutual funds, providing discretionary portfolio management across global, international, and regional equity strategies. It is authorized and regulated in the UK and is also registered with the U.S. Securities and Exchange Commission as an investment adviser. The firm files with the SEC under CIK #0001085972 as an institutional investment manager and submits Form 13F reports to disclose its U.S.-listed long equity and certain equity-like positions. These filings cover both direct U.S. holdings and American Depositary Receipts (ADRs) where applicable, giving a partial view of Baillie Gifford Overseas Ltd’s global equity implementation from a U.S.-regulatory perspective. At the partnership level, Baillie Gifford is governed by a group of partners led by a Joint Senior Partner structure, with Andrew Telfer in a chief-executive capacity across the organization, including Baillie Gifford Overseas Ltd. The firm’s client base spans public and corporate pension plans, sovereign and other institutional investors, sub-advisory relationships for pooled vehicles, and other sophisticated allocators seeking long-term, growth-oriented equity mandates. The 13F reports disclose only part of the firm’s global footprint, but they provide a structured dataset of U.S.-listed exposures that can be examined over time, forming the backbone of any analysis of its U.S.-reportable equity activity.

Baillie Gifford Overseas Ltd is strongly associated with a long-term, high-conviction global growth philosophy. Its portfolios typically seek companies capable of delivering exceptional growth in cash flows and business value over long horizons, often a decade or more. The firm emphasizes the asymmetry of equity markets—where a small number of outstanding winners can drive much of the long-run capital trajectory—and is willing to tolerate meaningful interim volatility in exchange for exposure to companies it believes can compound at high rates. Core elements of the approach include: - Bottom-up fundamental research focused on business models, competitive advantage, reinvestment opportunities, and management alignment rather than short-term earnings beats. - Preference for scalable, innovative franchises, frequently in technology, consumer internet and e-commerce, digital platforms, software and cloud infrastructure, life sciences, and other areas with large addressable markets. - Willingness to back earlier-stage or less widely owned growth companies when the long-run opportunity is judged to be underappreciated by the market. - Extended holding periods, with an expectation that the majority of value creation may occur well beyond typical three-to-five-year evaluation windows. This philosophy results in concentrated, benchmark-agnostic portfolios with high active share relative to traditional indices. The 13F-disclosed sleeve for Baillie Gifford Overseas Ltd commonly shows significant representation of global growth leaders, disruptive innovators, and secular compounders listed in the U.S., complemented by ADRs of non-U.S. companies where those positions meet 13F-reporting thresholds. Within this framework, sector weights are an outcome of stock selection rather than a target. As a result, technology, communication services, consumer discretionary, and healthcare are often overweighted relative to broad global benchmarks, while more traditional value-oriented sectors such as banks, energy, and some mature industrials may be underrepresented. From the perspective of an allocator using regulatory data, the firm’s 13F Portfolio Composition provides a lens into how this growth philosophy translates into U.S.-listed holdings: the degree of concentration in top names, the thematic emphasis on innovation, and the persistence of positions across multiple reporting periods. A 13F-based reconstruction can then be used to build a synthetic Historical Track Record for the U.S.-reportable growth sleeve, with the important caveat that it excludes many non-U.S. securities managed by the firm.

Baillie Gifford Overseas Ltd is a long-term, high-conviction global growth manager whose U.S.-reportable holdings reflect a strong preference for innovative, scalable businesses with substantial reinvestment opportunities. The combination of extended investment horizons, benchmark-agnostic stock selection, and meaningful concentration in a select group of growth franchises leads to a distinctive capital trajectory that can diverge materially from traditional benchmarks over multi-year periods. The firm’s 13F History provides a structured record of how its U.S.-listed and ADR positions have evolved: which companies have remained enduring core holdings, where new growth themes have been introduced, and how concentration and sector balance have shifted through different market cycles. For allocators, analyzing this data set illuminates the persistence of convictions, the extent of portfolio turnover, and the degree to which capital has been allocated to earlier-stage versus more established growth names. By integrating holdings data into a 13F-aware analytics framework, investors can reconstruct the visible portion of the firm’s global growth implementation, evaluate concentration and sector tilts, and estimate risk and compounding characteristics. Combining 13F Portfolio Composition with derived metrics such as Max Drawdown Depth and Sharpe Ratio offers a disciplined way to assess the trade-off between long-horizon growth optionality and interim volatility in the U.S.-reportable sleeve. At the same time, any such analysis remains partial. Many of Baillie Gifford Overseas Ltd’s most distinctive positions are in non-U.S. markets outside the scope of Form 13F, and mandate-level nuances (e.g., specific benchmarks, regional constraints, or client objectives) are not visible in the filings. A central diagnostic question for further work is how a growth-centric, innovation-focused portfolio of the type observed in the 13F data would behave under a prolonged regime of value and dividend leadership, higher real interest rates, and more intensive regulatory scrutiny of dominant technology and healthcare franchises.

The risk profile of Baillie Gifford Overseas Ltd, as observed through its 13F holdings, is dominated by growth and innovation exposures rather than by benchmark-relative tracking constraints. Key risk characteristics include: - Style and factor risk: A pronounced tilt toward growth, quality, and often momentum factors means the portfolio can experience extended periods of underperformance relative to value or cyclical-led markets. When investor preference shifts toward lower-multiple or more asset-heavy businesses, growth-oriented portfolios can face both multiple compression and heightened volatility. - Concentration and idiosyncratic risk: Baillie Gifford portfolios typically hold a focused list of high-conviction positions, with a material share of capital in the largest holdings. This amplifies exposure to company-specific outcomes—both positive (outsized compounders) and negative (thesis breaks or regulatory shocks impacting key names). - Sector and thematic risk: Overweights in technology, internet, and healthcare create sensitivity to regulatory regimes (e.g., antitrust or data privacy for platforms, pricing and reimbursement for healthcare), as well as to changes in capital markets’ willingness to fund high-growth business models. - Path and liquidity risk: Some holdings may be in rapidly growing but less mature companies with narrower trading liquidity or higher event risk. These can exhibit sharp drawdowns during risk-off episodes or sentiment reversals in growth equities. Using the time series of holdings derived from 13F filings under CIK #0001085972, allocators can construct a U.S.-listed equity proxy for the strategy and evaluate historical volatility, downside characteristics, and risk-adjusted outcomes. Metrics such as Max Drawdown Depth and synthetic Sharpe Ratio for the reconstructed sleeve can be estimated from this data, providing an empirical sense of how the visible portion of the strategy’s compounding behavior has responded to different market regimes—such as growth-led bull markets, value rotations, and broad risk-off environments. It is critical to recognize, however, that Form 13F omits non-U.S. listed equities, private holdings (if any), derivatives, and shorts, and only captures long holdings above reporting thresholds. Consequently, 13F-based risk analytics describe the behavior of the U.S.-reportable long equity subset, not the entirety of Baillie Gifford Overseas Ltd’s global mandates.